03:08 , Sep 23, 2017 |  BioCentury  |  Emerging Company Profile

Selective suppression

Kezar Life Sciences Inc. is targeting the immunoproteasome to selectively suppress the hyperactive immune cells that drive autoimmunity. The company expects its biologics to have the rapid onset and broad activity of steroids, but without...
00:51 , Jan 11, 2017 |  BC Innovations  |  Distillery Therapeutics

Transplant

INDICATION: Graft rejection; heart transplant rejection Mouse studies identified a dipeptide inhibitor of PSMB8 that could help prevent skin and heart transplant rejection. Chemical synthesis and testing in in vitro activity assays of dipeptides yielded a...
07:00 , Oct 12, 2009 |  BioCentury  |  Emerging Company Profile

BerGenBio: Controlling Interference

Conventional RNAi methods can neither control nor vary the extent to which a protein's expression is blocked, and so provide only rough insights into target function at one level of inhibition. BerGenBio A/S says its...
07:00 , Jun 25, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Rheumatoid arthritis (RA) ...
07:00 , Jun 25, 2009 |  BC Innovations  |  Targets & Mechanisms

Proteasome progress

Although animal studies have shown that proteasome inhibitors can prevent self-antigen and cytokine production and thus may have potential utility in autoimmune diseases, the toxicity of the drugs makes them unsuitable for such chronic conditions.1...
07:00 , Jun 22, 2009 |  BC Week In Review  |  Clinical News

Proteolix preclinical data

In mouse models of rheumatoid arthritis (RA), PR-957 reversed signs of disease and reduced cellular infiltration, cytokine production and autoantibody levels. In vitro and in vivo, PR-957 blocked presentation of proteasome prosome macropain subunit...